시장보고서 | 연간정보서비스 | 맞춤형시장조사 | 메일링 | 비교리스트
세계의 신종 코로나 바이러스 감염증(COVID-19) 백신 개발 도구 시장 : 기술별·애플리케이션별·최종 용도별 시장 규모, 시장 점유율 및 동향 분석, 부문별 예측(2021-2028년)
COVID-19 Vaccine Development Tools Market Size, Share & Trends Analysis Report By Technology, By Application (Vaccine Process Development, Vaccine Research), By End Use (CROs, Pharma & Biopharma Companies), And Segment Forecasts, 2021 - 2028
상품코드 : 1019655
리서치사 : Grand View Research, Inc.
발행일 : 2021년 07월
페이지 정보 : 영문 150 Pages
US $ 5,950 ￦ 7,867,000
Unprintable PDF (Single User License)
US $ 6,950 ￦ 9,189,000
Printable PDF (5-User License)
US $ 8,950 ￦ 11,833,000
Printable PDF (Enterprise License)


한글목차

세계의 신종 코로나 바이러스 감염증(COVID-19) 백신 개발 도구 시장 규모는 2021년부터 2021년까지 8.6%의 CAGR로 확대하고, 2028년에 309억 달러에 달할 것으로 예상되고 있습니다.

전세계의 전문가가 COVID-19의 백신 주사를 개발하기 위해 실행 가능한 백신 후보의 특정 및 개발을 급속하게 추진하고 있습니다. 이는 전세계적으로 SARS-CoV-2의 지속적인 참상에 기인하고 있습니다. 또한 SARS-CoV-2 감염의 두번째 파도는 북반구의 겨울의 시작과 일치 할 것으로 예상되며, 팬데믹 타임 라인의 주요시기를 보여줍니다.

따라서 가능한 백신 주사의 개발은 COVID-19의 전세계적 영향을 줄이기 위해 필수적입니다. 이 필요성을 인식하고 COVID-19에 대한 효과적인 접종의 개발에 종사하는 사업체는 4개의 잠재적인 주요 백신 후보, 즉 mRNA 재조합, 불활화 및 복제 결핍 바이러스 벡터를 목표로하고 있습니다. 이러한 4개의 후보가 중점 분야이며, 후보의 특성화를 위한 질량 분석 및 크로마토 그래피의 통합은 위의 모든 후보의 개발 과정에서 공통적으로 적용됩니다.

세계의 신종 코로나 바이러스 감염증(COVID-19) 백신 개발 도구(COVID-19 Vaccine Development Tools) 시장에 대해 조사 분석 했으며, 시장 및 산업 전망/부문별·지역별 전망/경쟁 상황 등 체계적인 정보를 제공합니다.

목차

제1장 조사 방법 및 범위

제2장 개요

제3장 COVID-19 백신 개발 도구 시장의 변수 동향 및 범위

제4장 비즈니스 환경 분석

제5장 COVID-19 백신 개발 도구 시장 : 기술별 시장 분석

제6장 COVID-19 백신 개발 도구 시장 : 애플리케이션별 시장 분석

제7장 COVID-19 백신 개발 도구 시장 : 최종 용도 사업 분석

제8장 지역별 시장 분석

제9장 기업 개요

LYJ 21.08.06
영문 목차

영문목차

COVID-19 Vaccine Development Tools Market Growth & Trends

The global COVID-19 vaccine development tools market size is expected to reach USD 30.9 billion by 2028, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 8.6% from 2021 to 2028. Research professionals across the globe, are rapidly persuading the identification and development of viable candidates to develop COVID-19 immunization shots. This is attributed to the persisting devastation of SARS-CoV-2 across the globe. Additionally, second waves of SARS-CoV-2 infection were expected to coincide with the beginning of winter in the northern hemisphere, indicating the crucial period in the pandemic's timeline.

Thus, the development of a viable immunization shot is imperative to mitigate the global impact of COVID-19. Acknowledging this need, entities engaged in the development of effective inoculation against COVID-19, are aiming at 4 potential key vaccine candidates, namely, mRNA, recombinant, inactivated, and replication-deficient viral vector. These 4 candidates are the key areas of focus, and the integration of mass spectrometry and chromatography for candidate characterization is common across the development process of all the above candidates.

The spike protein (S-protein) is the most preferred target site with respect to the COVID-19 vaccine target discovery. This is attributed to the fact that the S-proteins are spread throughout the surface of the COVID-19 molecule, which enables attachment to host cell receptors, in turn ensuring easy entry of the virus into the host cell. Active government initiatives aimed at enabling the fast-track development of COVID-19 boosters are expected to create a favorable environment for entities operating in the industry.

For instance, in April 2020, the Access to COVID-19 Tools (ACT) Accelerator was launched aimed at speeding up the delivery and development of COVID-19 boosters. This initiative is inclusive of a health systems connector that supports the delivery of required resources to countries. The tools are also pooled under the umbrella mechanism, namely, the COVAX Facility to ensure effective procurement as well as equitable access to, COVID-19 vaccination and development tools. The ACT Accelerator targets to deliver around 2 billion doses by the end of 2021, across the globe.

COVID-19 Vaccine Development Tools Market Report Highlights

Laboratory technologies have generated the highest revenue in 2020 and this segment is anticipated to maintain its dominance throughout the forecast period

Significant growth in the adoption of pre-existing laboratory technologies such as PCR, 3D and 2D cell culture products, and flow cytometry is attributive to the segment's dominance

The PCR and qPCR segment dominated the market in terms of revenue share in 2020

The WHO recommends the implementation of rRT-PCR in surveillance of participants for effective COVID-19 vaccine evaluation, which has supplemented a significant surge in the uptake of PCR products

Detecting new mutations in SARS-CoV-2 enables research professionals to reconstruct unknown infection routes along with establishing a molecular basis for COVID-19 vaccine design

This has widely promoted the usage of NGS particularly across molecular typing and genomic epidemiology applications, making it the fastest-growing segment throughout the forecast period

Interactive web tools have emerged as dominant online technologies employed in COVID-19 vaccine development and research

Online interactive web tools have gained sufficient traction amongst the researchers and vaccine developers as these entail interactive graphs, maps, and dashboards that assist in effective monitoring of vaccine development while avoiding any misinformation

Vaccine research has witnessed the highest penetration of COVID-19 vaccine development tools, leading to the segment's largest share in 2020

Large-scale adoption of tools associated with nucleic acid isolation and purification, real-time PCR, Sanger sequencing, mass spectrometry, and NGS among others has contributed to the segment's dominance

The contract research organization (CROs) end-use segment is expected to grow at a fast pace through 2021 - 2028. Partnerships with CROs are proving integral as they ensure access to a vast number of resources along with expanded expertise

North America dominated the market and accounted for the largest revenue share in 2020; U.S. ranked 1st in this region, in terms of revenue

More than 20% of the vaccines being developed across the globe hail from the U.S., thus, providing immense lucrative opportunities for the market players operational in the country

Table of Contents

Chapter 1 Methodology And Scope

Chapter 2 Executive Summary

Chapter 3 Covid-19 Vaccine Development Tools Market Variables, Trends & Scope

Chapter 4 Business Environment Analysis

Chapter 5 Covid-19 Vaccine Development Tools Market: Technology Business Analysis

Chapter 6 Covid-19 Vaccine Development Tools Market: Application Business Analysis

Chapter 7 Covid-19 Vaccine Development Tools Market: End-Use Business Analysis

Chapter 8 Regional Business Analysis

Chapter 9 Company Profile

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기